Objectives: To evaluate abortion and fetal congenital anomaly rates in women previously submitted to radioiodine therapy for differentiated thyroid carcinoma. Study design: A case-control study of 108 pregnant women, 48 cases whose pregnancies were evaluated after they had undergone radioiodine therapy for differentiated thyroid carcinoma, and the control group consisted of 60 healthy pregnant women. Results: Of a total of 66 pregnancies, 14 conceived within the first year, 51 one or more years after the last administration of 131 I, the medical record of one patient was not available. The interval between the last radioiodine therapy administration and conception ranged from 1 month to 10 years. There were a total of 4 miscarriages, 2 of them for unknown reasons. There was one case of congenital anomaly and two preterms birth. Nine women presented the following pregnancy events: placental insufficiency, hypertensive crisis, placental detachment, risk of miscarriage, preterm labour and four miscarriages. No statistical difference was observed between the studied and control groups. Conclusion: Radioiodine was followed by no significant increase in untoward effects in neither the pregnancy nor the offspring. Objetivo: Avaliar a taxa de aborto e anomalia congênita em mulheres que engravidaram após radioiodoterapia para carcinoma diferenciado de tireóide. Pacientes e método: Estudo de caso controle com 108 mulheres, 48 submetidas à radioiodoterapia para carcinoma diferenciado de tireóide e 60 mulheres saudáveis (grupo controle). Resultados: De 66 gestações (grupo de pacientes que receberam radioiodo), 14 ocorreram no primeiro ano e 51 mais de um ano após a administração do 131 I. Não foi possível coletar dados de uma paciente. O intervalo entre a última dose de 131 I e a concepção variou de 1 mês a 10 anos. Ocorreram 4 abortos, 2 de causas desconhecidas. Houve 1 caso de anomalia congênita e 2 pretermos. Nove pacientes que receberam 131 I apresentaram intercorrências durante a gravidez: insuficiência placentária, crise hipertensiva, descolamento de placenta, ameaça de aborto, trabalho de parto prematuro e 4 abortos. Não houve diferença estatística entre o grupo estudado e o controle. Conclusão: O uso da radioiodoterapia para carcinoma diferenciado de tireóide em mulheres não foi relacionado com aumento de efeitos adversos nas mães e suas proles.
A radioiodoterapia tem conseguido desempenhar um papel significante no tratamento do carcinoma diferenciado de tireóide. A literatura é limitada em relação a possíveis efeitos secundários do 131I, embora o interesse tenha aumentado nesse campo. A importância de se saber mais sobre os efeitos mutagênicos da radiação em filhos de mães expostas ao 131I para tratamento do carcinoma diferenciado de tireóide é devida à possibilidade de ocorrência de abortos, anormalidades genéticas e aparecimento de malignidades nas crianças. Nesta revisão da literatura vários estudos têm demonstrado a segurança desse tipo de tratamento em mulheres na idade fértil, sendo apenas aconselhadas a evitar gravidez pelo período de, pelo menos, um ano após a administração da radioiodoterapia.
Diabetic muscle infarction (DMI) is an uncommon complication of long standing diabetes (DM). This abnormal condition may occur in poorly controlled patients with type 1 and 2 DM with established microangiopathy. Clinical presentation is usually acute with severely painful swelling of the affected muscle, which persists for many weeks and has spontaneous recovery. Albeit uncertain, its etiology is associated with microangiopathy with occlusion of small arteries. This condition is diagnosed by biopsy although results from T2 -- weight magnetic resonance are typical. Pain management, bed rest and careful metabolic control are the treatment of choice. We report 3 cases of DMI admitted to a general hospital who were initially misdiagnosed and led to inadequate treatment and management at onset of the condition. We emphasize the clinical, image and histological aspects of DMI in order to allow early awareness of this uncommon condition, avoiding unnecessary delay as well as hastening appropriate treatment.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.